Open-Label, Non Randomized Phase 2 Study With Safety Run-In
Open-Label, Non Randomized Phase 2 Study With Safety Run-In Evaluating Efficacy and Safety of PQR309 in Patients With Relapsed or Refractory Lymphoma
Sponsor: Churchill Hospital
Listed as NCT02249429, this PHASE2 trial focuses on Lymphoma, Malignant and remains completed. Sponsored by Churchill Hospital, it has been updated 13 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Oct 2021 — Apr 2022 [monthly]
Completed PHASE2
▶ Show 8 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE2
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE2
Phase: PHASE1_PHASE2 → PHASE2
-
Apr 2019 — Oct 2019 [monthly]
Completed PHASE1_PHASE2
-
Nov 2018 — Apr 2019 [monthly]
Completed PHASE1_PHASE2
Status: Recruiting → Completed
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE1_PHASE2
-
May 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — May 2017 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
May 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Churchill Hospital
- Clinical Center Kragujevac
- Clinical Center Nis, Nis
- Institut Curie
- Institute for Oncology and Radiology Serbia, Belgrade
- PIQUR Therapeutics AG
- Royal Marsden NHS Foundation Trust
- University Clinical Center, Sarajevo
- University Clinical Centre of Republic of Srpska
- University College London Hospitals
- University of Haifa
- Weill Medical College of Cornell University
For direct contact, visit the study record on ClinicalTrials.gov .